Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-22-019841
Filing Date
2022-05-12
Accepted
2022-05-12 16:03:40
Documents
49
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q dice-10q_20220331.htm   iXBRL 10-Q 2167490
2 EX-31.1 dice-ex311_480.htm EX-31.1 20419
3 EX-31.2 dice-ex312_479.htm EX-31.2 20328
4 EX-32.1 dice-ex321_478.htm EX-32.1 9801
5 EX-32.2 dice-ex322_477.htm EX-32.2 9675
  Complete submission text file 0001564590-22-019841.txt   5720657

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA dice-20220331.xsd EX-101.SCH 32922
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE dice-20220331_cal.xml EX-101.CAL 41559
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE dice-20220331_def.xml EX-101.DEF 92977
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE dice-20220331_lab.xml EX-101.LAB 263392
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dice-20220331_pre.xml EX-101.PRE 185629
43 EXTRACTED XBRL INSTANCE DOCUMENT dice-10q_20220331_htm.xml XML 784608
Mailing Address 279 E. GRAND AVENUE, SUITE 300, LOBBY B SOUTH SAN FRANCISCO CA 94080
Business Address 279 E. GRAND AVENUE, SUITE 300, LOBBY B SOUTH SAN FRANCISCO CA 94080 650-566-1402
DICE Therapeutics, Inc. (Filer) CIK: 0001645569 (see all company filings)

EIN.: 472286244 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40794 | Film No.: 22917695
SIC: 2834 Pharmaceutical Preparations